Abstract:It is becoming increasingly clear that alternative splicing enables the complex development and homeostasis of higher organisms. To gain a better understanding of how splicing contributes to regulatory pathways, we have developed an alternative splicing library approach for the identification of alternatively spliced exons and their flanking regions by alternative splicing sequence enriched tags sequencing. Here, we have applied our approach to mouse melan-c melanocyte and B16-F10Y melanoma cell lines, in whic… Show more
“…Differential splicing patterns in mouse melanocytes and mouse melanoma cell lines was recently reported (49). A spliced isoform of PIAS3 in which PIAS3 82-132 is excluded was found to be expressed in mouse melanoma but not in mouse melanocytes.…”
Protein inhibitor of activated STAT3 (PIAS3) functions in vivo as a key molecule in suppressing the transcriptional activity of both microphthalmia transcription factor (MITF) and STAT3, two transcription factors that play a major role in the development, phenotypic expression, and survival of mast cells and melanocytes. In the present study we have investigated the role played by PIAS3 in the regulation of cell cycle in mast cells and melanocytes. We have characterized the biological role of a 23-aa domain derived from PIAS3 that induces apoptosis in these cells by inhibiting the transcriptional activity of both MITF and STAT3. This PIAS3 inhibitor peptide could serve as the beginning of an in depth study for the development of peptide inhibitors for MITF and STAT3.
“…Differential splicing patterns in mouse melanocytes and mouse melanoma cell lines was recently reported (49). A spliced isoform of PIAS3 in which PIAS3 82-132 is excluded was found to be expressed in mouse melanoma but not in mouse melanocytes.…”
Protein inhibitor of activated STAT3 (PIAS3) functions in vivo as a key molecule in suppressing the transcriptional activity of both microphthalmia transcription factor (MITF) and STAT3, two transcription factors that play a major role in the development, phenotypic expression, and survival of mast cells and melanocytes. In the present study we have investigated the role played by PIAS3 in the regulation of cell cycle in mast cells and melanocytes. We have characterized the biological role of a 23-aa domain derived from PIAS3 that induces apoptosis in these cells by inhibiting the transcriptional activity of both MITF and STAT3. This PIAS3 inhibitor peptide could serve as the beginning of an in depth study for the development of peptide inhibitors for MITF and STAT3.
“…Increasing evidence points to a central role of SNXs for vesicle trafficking processes in oncogenesis and tumor suppression, and SNX1, SNX2, SNX10, and SNX16 have been shown to be involved in tumorigenesis (14,(34)(35)(36)(37). SNX1 is the mammalian homologue of the yeast vacuole protein-sorting molecule, Vps5p, and is implicated in endosome-to-lysosome sorting of cell surface receptors, including multiple receptor tyrosine kinases (EGFR, PDGFR, the insulin receptor, and the transferrin receptor; ref.…”
MicroRNAs (miRNAs) are strongly implicated in cancer but their specific roles and functions in the major cancers have yet to be fully elucidated. In this study, we defined the oncogenic significance and function of miR-95, which we found to be elevated in colorectal cancer (CRC) tissues by microarray analysis. Evaluation of an expanded CRC cohort revealed that miR-95 expression was up-regulated in nearly half of the tumors examined (42/87) compared with the corresponding noncancerous tissues. Ectopic overexpression of miR-95 in human CRC cell lines promoted cell growth in vitro and tumorigenicity in vivo, whereas RNAi-mediated silencing of miR-95 decreased cell growth ratio. Mechanistic studies revealed that miR-95 repressed the expression of reporter gene coupled to the 3 0 -untranslated region of sorting nexin 1 (SNX1), whereas miR-95 silencing up-regulated SNX1 expression. Moreover, miR-95 expression levels correlated inversely with SNX1 protein levels in human CRC tissues. RNAi-mediated knockdown of SNX1 phenocopied the proliferation-promoting effect of miR-95, whereas overexpression of SNX1 blocked miR-95-induced proliferation of CRC cells. Taken together, these results demonstrated that miR-95 increases proliferation by directly targeting SNX1, defining miR-95 as a new oncogenic miRNA in CRC. Cancer Res; 71(7); 2582-9. Ă2011 AACR.
“…There is growing evidence demonstrating the correlation between specific alternatively spliced variants and the malignant phenotype as well as drug resistance to chemotherapy in cancer patients (31). Comprehensive mapping of cancer-specific alternative spliced genes is underway to resolve the complex patterns of spliced variants in cancer cells (53). PTB is one of over 100 known splicing factors and regulators that influence alternative splicing decisions.…”
RNA processing is altered during malignant transformation, and expression of the polypyrimidine tract-binding protein (PTB) is often increased in cancer cells. Although some data support that PTB promotes cancer, the functional contribution of PTB to the malignant phenotype remains to be clarified. Here we report that although PTB levels are generally increased in cancer cell lines from multiple origins and in endometrial adenocarcinoma tumors, there appears to be no correlation between PTB levels and disease severity or metastatic capacity. The three isoforms of PTB increase heterogeneously among different tumor cells. PTB knockdown in transformed cells by small interfering RNA decreases cellular growth in monolayer culture and to a greater extent in semi-solid media without inducing apoptosis. Down-regulation of PTB expression in a normal cell line reduces proliferation even more significantly. Reduction of PTB inhibits the invasive behavior of two cancer cell lines in Matrigel invasion assays but enhances the invasive behavior of another. At the molecular level, PTB in various cell lines differentially affects the alternative splicing pattern of the same substrates, such as caspase 2. Furthermore, overexpression of PTB does not enhance proliferation, anchorage-independent growth, or invasion in immortalized or normal cells. These data demonstrate that PTB is not oncogenic and can either promote or antagonize a malignant trait dependent upon the specific intra-cellular environment.The polypyrimidine tract-binding protein (PTB), 3 also termed heterogeneous nuclear ribonucleoprotein I, is a 57-kDa RNA-binding protein that binds preferentially to pyrimidinerich sequences (1-3). PTB contains four RNA recognition motifs (RRMs). RRM 1 and 2 at the N terminus of the protein are involved in the dimerization of PTB, whereas RRM 3 and 4 are responsible for high affinity interactions with RNA (4, 5). PTB has been shown to be involved in many aspects of pre-mRNA and mRNA metabolism. PTB participates in pre-mRNA splicing (6) and acts as a splicing repressor in alternative splicing of pre-mRNA (5, 7-12). PTB is also involved in 3Đ end polyadenylation of pre-mRNA (13-15) and is important for translational regulation of certain RNA transcripts through internal ribosome entry sites (16 -20). In addition, PTB shuttles between the nucleus and the cytoplasm (21), which is regulated through phosphorylation by 3Đ,5Đ-cAMP-dependent protein kinase (22).Alternative splicing is a process that allows multiple different proteins to be made from the same pre-mRNA by either including or excluding particular exons during pre-mRNA splicing. PTB plays a key role in alternative site selection for many gene products by acting as a splicing repressor that prevents the inclusion of target exons (11,(23)(24)(25). Changes in alternative splicing sites have been previously correlated with malignant transformation (26 -29), and the expression level of PTB has been found elevated in transformed cells. Such an elevation is responsible for the increases...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citationsâcitations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.